Press release
Sarcopenia Pipeline Assessment, 2023 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | NMD Pharma, Turn Biotechnologies, Oncocross, Biophytis
"Sarcopenia Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Sarcopenia Market.
The Sarcopenia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Sarcopenia Pipeline Report: https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Sarcopenia treatment therapies with a considerable amount of success over the years.
• Sarcopenia companies working in the treatment market are NMD Pharma, Turn Biotechnologies, Oncocross, Biophytis, MyMD Pharmaceuticals, and others, are developing therapies for the Sarcopenia treatment
• Emerging Sarcopenia therapies in the different phases of clinical trials are- NMDP 05, TRN 005, OC514, BIO101, MYMD-1, and others are expected to have a significant impact on the Sarcopenia market in the coming years.
• In July 2023, Muscle mass, strength, and performance are severely hampered with age in sarcopenia, a musculoskeletal condition. The aged, sedentary people, and those with comorbidities that have an impact on the musculoskeletal system or limit physical exercise are the groups most frequently affected by Sarcopenia
• In July 23, The Phase I worldwide clinical study of OC514 for the treatment of sarcopenia and other uncommon muscle illnesses has been completed by ncocross in Australia.
• OC514 is being developed as a drug-drug combination treatment for preventing sarcopenia, a syndrome characterised by a widespread loss of skeletal muscle mass, using the proprietary AI platform RAPTOR AI
Sarcopenia Overview
Muscle mass, strength, and performance are severely hampered with age in sarcopenia, a musculoskeletal condition. The aged, sedentary people, and those with comorbidities that have an impact on the musculoskeletal system or limit physical exercise are the groups most frequently affected by sarcopenia.
Get a Free Sample PDF Report to know more about Sarcopenia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Sarcopenia Drugs Under Different Phases of Clinical Development Include:
• NMDP 05: NMD Pharma
• TRN 005: Turn Biotechnologies
• OC514: Oncocross
• BIO101 Biophytis
• MYMD-1: MyMD Pharmaceuticals
• Sarconeos (BIO101): Biophytis
•
Sarcopenia Route of Administration
Sarcopenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Sarcopenia Molecule Type
Sarcopenia Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Sarcopenia Pipeline Therapeutics Assessment
• Sarcopenia Assessment by Product Type
• Sarcopenia By Stage and Product Type
• Sarcopenia Assessment by Route of Administration
• Sarcopenia By Stage and Route of Administration
• Sarcopenia Assessment by Molecule Type
• Sarcopenia by Stage and Molecule Type
DelveInsight's Sarcopenia Report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Sarcopenia product details are provided in the report. Download the Sarcopenia pipeline report to learn more about the emerging Sarcopenia therapies at:
https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Sarcopenia Therapeutics Market include:
Key companies developing therapies for Sarcopenia are - Abbott Nutrition, GSK PLC, Nestle Health Science, Sanofi SA, Bayer AG, Novartis AG, Metagenics LLC, Wellona Pharma, Intas Pharmaceuticals Ltd, Perrigo Company PLC, Dr. Jockers Store, and others
Sarcopenia Pipeline Analysis:
The Sarcopenia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Sarcopenia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sarcopenia Treatment.
• Sarcopenia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Sarcopenia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sarcopenia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Sarcopenia drugs and therapies-
https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Sarcopenia Pipeline Market Drivers
• Increase in Prevalence of Sarcopenia, increase in Research and development activities are some of the important factors that are fueling the Sarcopenia Market.
Sarcopenia Pipeline Market Barriers
• However, complications of Sarcopenia treatment, lack of awareness about the disease and other factors are creating obstacles in the Sarcopenia Market growth.
Scope of Sarcopenia Pipeline Drug Insight
• Coverage: Global
• Key Sarcopenia Companies: NMD Pharma, Turn Biotechnologies, Oncocross, Biophytis, MyMD Pharmaceuticals, and others
• Key Sarcopenia Therapies: NMDP 05, TRN 005, OC514, BIO101, MYMD-1, and others
• Sarcopenia Therapeutic Assessment: Sarcopenia current marketed and Sarcopenia emerging therapies
• Sarcopenia Market Dynamics: Sarcopenia market drivers and Sarcopenia market barriers
Request for Sample PDF Report for Sarcopenia Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Sarcopenia Report Introduction
2. Sarcopenia Executive Summary
3. Sarcopenia Overview
4. Sarcopenia- Analytical Perspective In-depth Commercial Assessment
5. Sarcopenia Pipeline Therapeutics
6. Sarcopenia Late Stage Products (Phase II/III)
7. Sarcopenia Mid Stage Products (Phase II)
8. Sarcopenia Early Stage Products (Phase I)
9. Sarcopenia Preclinical Stage Products
10. Sarcopenia Therapeutics Assessment
11. Sarcopenia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Sarcopenia Key Companies
14. Sarcopenia Key Products
15. Sarcopenia Unmet Needs
16 . Sarcopenia Market Drivers and Barriers
17. Sarcopenia Future Perspectives and Conclusion
18. Sarcopenia Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Sarcopenia Market https://www.delveinsight.com/report-store/sarcopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Sarcopenia-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Sarcopenia Epidemiology https://www.delveinsight.com/report-store/sarcopenia-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Sarcopenia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products
Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Sarcopenia Pipeline Assessment, 2023 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | NMD Pharma, Turn Biotechnologies, Oncocross, Biophytis here
News-ID: 3129641 • Views: …
More Releases from DelveInsight Business Research
Immune Checkpoint Inhibitors Market Outlook 2034: Competitive Landscape, Pipelin …
DelveInsight's latest report, "Immune Checkpoint Inhibitors Market Forecast (2020-2034)", provides an in-depth analysis of one of the most transformative areas in oncology. According to DelveInsight estimates, the Immune Checkpoint Inhibitors (ICI) market is expected to grow at a decent CAGR throughout the forecast period, driven by the rising global burden of cancer, advances in immuno-oncology, increasing healthcare expenditures, and the anticipated approval of novel ICIs across the 7MM [the United…
HPK1 Inhibitors Market Outlook 2034: Competitive Landscape, Pipeline Advancement …
(Albany, USA, September 2025) - DelveInsight has released its latest report, "HPK1 Inhibitor Competitive Landscape And Market Forecast - 2034," delivering an in-depth analysis of the rapidly evolving HPK1 inhibitor market. The report offers a comprehensive overview of the epidemiology, drug uptake, treatment landscape, competitive intelligence, and market dynamics shaping the outlook of HPK1 inhibitors across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
To know…
Focal Adhesion Kinase (FAK) Inhibitors Market Outlook 2034: Scientific Advances, …
(Albany, USA, September 2025) - Focal Adhesion Kinase (FAK), also known as PTK2, has emerged as one of the most promising molecular targets in oncology research and therapy development. Encoded by the PTK2 gene, FAK is a non-receptor tyrosine kinase critically involved in signal transduction mediated by growth factor receptors and integrins. Increasing evidence shows that overexpression of FAK is directly associated with tumor progression, therapy resistance, and poor clinical…
Thyroid Eye Disease Market Set for Robust Expansion Through 2034, DelveInsight R …
DelveInsight's "Thyroid Eye Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Thyroid Eye Disease, historical and forecasted epidemiology as well as the Thyroid Eye Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Thyroid Eye Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Thyroid Eye Disease…
More Releases for Sarcopenia
Sarcopenia Market Size, Share & Growth Analysis 2034
Sarcopenia Market Overview
Sarcopenia is a condition characterized by the progressive loss of muscle mass, strength, and function, primarily affecting the elderly. This decline leads to increased frailty, higher risk of falls, and diminished quality of life. The rising global geriatric population has heightened the prevalence of sarcopenia, making it a significant public health concern. Consequently, there is a growing demand for effective treatments and interventions to manage and mitigate the…
Sarcopenia Treatment Market Future Prediction Report By 2030
Sarcopenia Treatment Market business research report assesses the current as well as upcoming performance of the market, also brand-new trends in the market. It provides product overview and highlights of product and application segments of the market including price, revenue, sales, sales growth rate, and market share by product. The market statistics within the report is displayed in a statistical format to offer a better understanding upon the market dynamics.…
Sarcopenia Treatment Market Report 2024 - Sarcopenia Treatment Market Size And G …
"The Business Research Company recently released a comprehensive report on the Global Sarcopenia Treatment Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The sarcopenia treatment market…
Sarcopenia Pipeline Insights Report 2023 (Updated)
(Albany, United States) As per DelveInsight's assessment, globally, the Sarcopenia Pipeline constitutes 8+ key companies continuously working towards developing 10+ Sarcopenia Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Sarcopenia Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Sarcopenia NDA approvals (if any), and product…
Global Sarcopenia Therapeutic Market Research Report 2023
The global Sarcopenia Therapeutic market was valued at US$ 2867.6 million in 2022 and is anticipated to reach US$ 3484.4 million by 2029, witnessing a CAGR of 3.3% during the forecast period 2023-2029.
view full report
https://reports.valuates.com/market-reports/QYRE-Auto-13K14453/global-sarcopenia-therapeutic
Sarcopenia Therapeutic Market
Sarcopenia is a syndrome caused by continuous loss of skeletal muscle mass, strength, and function.
The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
China is the largest consumption region of…
Sarcopenia - Drug Pipeline Landscape, 2022
Sarcopenia is a condition characterized by the loss of muscle mass and strength. It can occur due to a variety of reasons, including aging, inactivity, and certain chronic diseases.
Aging is the most common cause of sarcopenia. As people age, they tend to become less active and lose muscle mass. This process is known as age-related muscle loss or sarcopenia with aging.
Inactivity can also lead to sarcopenia. People who are not…
